Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Acetyl-CoA carboxylases (ACC1/ACC2) are important drug targets for NASH treatment. Gao et al developed WZ66, a novel inhibitor of ACCs that enables the decrease of de novo lipogenesis, the inactivation of Kupffer cells and hepatic stellate cells. WZ66 also altered the plasma lipids profile and gut microbiota composition.